![home-bg-image.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/82522f64-905d-4f5a-a75b-c5c2d4a54f01.jpg?nearlossless=1)
![Blue-Earth logo 900400.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/6634a5f7-b7f8-4eff-9441-ac8db7123c56.jpg?nearlossless=1)
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval for its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3)
Read more![Blue-Earth logo 900400.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/6634a5f7-b7f8-4eff-9441-ac8db7123c56.jpg?nearlossless=1)
Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer
Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer
Read more![Header_news_point_thumbnail.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/ecb411eb-7763-4fae-8720-719101e59f2e.jpg?nearlossless=1)
POINT Biopharma and SCINTOMICS Announce License Agreement
POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer.
Read more![PentixaPharm thumbnail news.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/e913252a-31d1-4c55-a77c-9a7fc3012b9e.jpg?nearlossless=1)
PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics
Feburary 6th 2020, WÜRZBURG, Germany--PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
Read more![technische-universitat-munchen-tum-logo.png](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/bb6e6c28-18bf-4b0f-a45f-2a4bff92f009.png?nearlossless=1)
Scintomics gewinnt TUM Presidential Entrepreneurship Award
Scintomics hat den diesjährigen TUM Presidential Entrepreneurship Award gewonnen. Das Unternehmen entwickelt radiopharmazeutische Technologien zur Krebsdiagnose.
Read more![PentixaPharm thumbnail news.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/e913252a-31d1-4c55-a77c-9a7fc3012b9e.jpg?nearlossless=1)
Scintomics and 1717 Life Science Ventures Team up
Scintomics and 1717 LSV to collaborate in the development of novel cancer diagnostics and treatment.
Read more- 1
- 2